Safety of dietary supplements including n-3 PUFA (Imark S&#174;) for the maintenance of remission in patients with Crohn's disease: A pilot study.

Safety of dietary supplements including n-3 PUFA (Imark S&#174;) for the maintenance of remission in patients with Crohn's disease: A pilot study. - Safety of dietary supplements including n-3 PUFA for CD.

Status

Active, not recruiting

Phases

Phase 1

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000012585

Enrollment

Registered

2014-01-10

Start date

2014-01-10

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Crohn&#39

Interventions

After 3 month intervention with Imark S supplements, to compare the data before ingestion with after each months intervention. 1 month(30 days): 1 bottle of ingestion/ a day 2 month(30 days): No ing

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1) Patients diagnosed with Crohn's diseases. 2) Patients expected over 3 month-survival from the first day of this study. 3) Patients who can orally ingestion. 4) Patients whose condition are in remission 5) Patients who are obtained with the prior written consent.

Exclusion criteria

Exclusion criteria: 1) Patients with the following diseases. (cirrhosis, chronic renal failure, diabetes with insulin therapy and so on) 2) Patients with steroid treatment 3) Patients with anti-TNF agents treatment 4) Patients with food allergy 5) Patients less than 20 years old. 6) Patients with xerosis cutis and impossible to measure body composition 7) Patients judged to be inappropriate for this study from the doctor in charge.

Design outcomes

Primary

Measure	Time frame
Safety study (Blood test indicators, inflammatory cytokine, CDAI)	—

Secondary

Measure	Time frame
Safety check depending on the number of intake.(100ml X 1 or 2 bottle) Efficacy check of maintenance for remission.(Using CDAI score)	—

Countries

Japan

Contacts

Public ContactAsuka Yasueda

Osaka University Graduate School of Medicine Department of Complementary and Alternative Medicine

a-yasueda@cam.med.osaka-u.ac.jp06-6879-3498

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026

Safety of dietary supplements including n-3 PUFA (Imark S&amp;#174;) for the maintenance of remission in patients with Crohn&#39;s disease: A pilot study.